ADXS

Company Update (NASDAQ:ADXS): Advaxis, Inc.’s Cancer Immunotherapies to be Featured in Three Poster Presentations at the 2015 SITC Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that three abstracts featuring Advaxis’s Lm Technology™ cancer immunotherapies have been selected …

Corey Williams — October 13, 2015, 9:15 AM EDT

H.C. Wainwright Remains Positive on Advaxis, Inc. (ADXS) Following FDA Clinical Hold

H.C.

Jason Cohen Jason Cohen — October 7, 2015, 1:04 PM EDT

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that last Thursday the company received verbal notice from the U.

Corey Williams — October 6, 2015, 4:08 PM EDT

Stock Update (NASDAQ:ADXS): First Human Patient Treated in Phase 1b Study of Advaxis, Inc.’s ADXS-HER2 in HER2 Expressing Solid Tumors

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was treated in a Phase 1b dose-escalation clinical study …

Corey Williams — September 28, 2015, 9:17 AM EDT

Advaxis, Inc.’s GOG0265 Results Could Pave the Way for AIM2CERV: H.C. Wainwright

In a research report released today, H.C.

Jason Cohen Jason Cohen — September 18, 2015, 10:50 AM EDT

Stock Update (NASDAQ:ADXS): Advaxis, Inc.’s Axalimogene Filolisbac Showed 38.5 Percent 12-Month Survival in Patients With Persistent/Recurrent Metastatic Cervical Cancer

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and the Gynecologic Oncology Group (GOG, now part of NRG Oncology), today announced clinical …

Corey Williams — September 17, 2015, 2:19 PM EDT

Company Update (NASDAQ:ADXS): FDA Awards Grant for Phase 2 Study of Advaxis, Inc.’s Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.

Corey Williams — September 14, 2015, 9:41 AM EDT

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Accepts Medical Visionary Award From the Farrah Fawcett Foundation for Collaborative Research in HPV-Associated Anal Cancer

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Farrah Fawcett Foundation honored Advaxis with the Foundation’s inaugural “Medical …

Corey Williams — September 10, 2015, 9:14 AM EDT

Company Update (NASDAQ:ADXS): Phase 2 Study of Advaxis’s Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that final clinical data from Stage 1 of the ongoing two-stage Phase …

Corey Williams — August 31, 2015, 9:13 AM EDT

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has entered into a licensing agreement with Knight Therapeutics …

Corey Williams — August 26, 2015, 8:28 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts